United Kingdom

People: AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

23 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Neels, Guido 

Mr. Guido J. Neels is an Independent Director of the AxoGen Inc. He has been an operating partner of Essex Woodlands Fund IX (“Essex”) since February 2013. Mr. Neels joined Essex as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 until retiring in November 2005, Mr. Neels served as COO of Guidant Corporation (“Guidant”), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant’s four operating units – Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 to December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 to 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co., Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 to 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors for Entellus Medical, Endologix and Bioventus. In addition to these Essex Woodlands portfolio company boards on which he serves, Mr. Neels also serves on the board of directors for Arsenal Medical, 480 Medical (which was spun out of Arsenal Medical), EndGenitor Technologies, and Christel House International (a not-for-profit organization).

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 109,249
Fiscal Year Total, USD 109,249

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --